CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma

Regorafenib is used for hepatocellular carcinoma (HCC), but its response does not last long, partly due to chemoresistance acquisition. We performed a clustered regularly interspaced short palindromic repeats (CRISPR)-based loss-of-function genetic screen and aimed to discover molecules involved in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers (Basel)
Hauptverfasser: Suemura, Shigeki, Kodama, Takahiro, Myojin, Yuta, Yamada, Ryoko, Shigekawa, Minoru, Hikita, Hayato, Sakamori, Ryotaro, Tatsumi, Tomohide, Takehara, Tetsuo
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6770429/
https://ncbi.nlm.nih.gov/pubmed/31540262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11091362
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge